PR Newswire PharmaOriginal article
Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
Partnershipproprietary peptide portfolioPositive
AI Analysis
Summary
Vector Science & Therapeutics entered into an exclusive long-term cGMP manufacturing agreement with LyoGenesis Plus, licensing its proprietary biomechanical peptide delivery platform for Vector's peptide portfolio to be sold directly to physicians and clinics.
Outcome Details
Exclusive cGMP manufacturing agreement and licensing of biomechanical peptide delivery platform
Importance:6/10
Sentiment:
0.60
partnershiplicensingmanufacturingpeptideplatform_technology
Read the original article
Published by PR Newswire Pharma on July 7, 2026 11:50 AM